Angioslide, a Natanya, Israel-based developer of “Embolic Capture Angioplasty” technology, has raised $6.3m in Series C funding.
The round was led by new investor TriVentures, with participation from existing investors Viola Partners, Agate and XT Investments.
The company intends to use the capital to expand in the USA, improve their product offering and validate the technology in additional vascular beds.
Founded in 2005 and led by Lihu Avitov, CEO, Angioslide is a privately held medical device company that has developed an Embolic Capture Angioplasty solution, PROTEUS™, which provides a combination of PTA balloon and embolic capture and removal.
The device received both FDA clearance and European CE Mark approval for lower limb use.
The company has regional offices in Europe and the US.